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Summary PMM is a water-soluble alternative to HMM. PMM has been administered as an intravenous
infusion to 17 patients in a Phase I clinical trial. The dose-limiting toxicities were nausea and vomiting which
were observed in all patients at 500mgm-2 and above. The dose was not escalated above 1300mg m 2 where
nausea and vomiting were severe, prolonged (>24h) and poorly controlled by anti-emetics. Haematological,
hepatic and renal toxicities were not observed. Neurological toxicity was not observed at low doses
(< 500mg/M2) but could not be determined at higher doses due to intensive anti-emetic therapy.
Pharmacokinetic studies (100-500mgm-2) indicated that PMM plasma levels are dose-dependent and that the
PMM disposition-phase half-life is prolonged in patients with abnormal liver function. It is concluded that
the severe toxicity of PMM will limit the clinical utility of this compound and hence Phase II trials are not
recommended.
Pentamethylmelamine (PMM) (Figure la) is the
monodemethylated analogue of hexamethylmel-
amine (HMM) (Figure lb). HMM is an s-triazine
derivative which has been in clinical use for
15 years. It has shown activity against a number
of tumour types including small cell lung
cancer, ovarian adenocarcinoma and malignant
lymphoma (Legha et al., 1976). More recently, it has
been reported that HMM is active against ovarian
carcinoma resistant to alkylating agents (Johnson et
al., 1978; Bonomi et al., 1979), lymphomas resistant
to standard therapy (Omura et al., 1981), and
Bilharzial bladder carcinoma (Gad-el-Mawla et al.,
1978). HMM is administered orally, its low aqueous
solubility preventing parenteral administration.
However, the absorption of orally administered
HMM is highly variable (D'Incalci et al., 1978).
Furthermore, in patients with disease which
obstructs the gastrointestinal tract, HMM cannot
be given. Thus an HMM analogue, suitable for
parenteral administration, was developed. In an
extensive structure-activity study (Cumber & Ross,
1977) two water soluble analogues of HMM were
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Figure 1 The structure of PMM (a) and HMM (b).
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identified as potential candidates for clinical trial,
namely PMM and N2,N4,N6-trimethyl-N2,N4,N6-
trimethylolmelamine. Of these two analogues,
PMM was chosen on the basis of its greater
chemical stability. PMM is 23 times more soluble
than HMM and has equivalent activity in a number
of experimental tumour test systems (Cumber &
Ross, 1977; Connors et al., 1977; Goldin et al.,
1981).
In the present study the results of the Phase I
clinical evaluation of PMM at the Royal Marsden
Hospital are reported. In addition to the clinical
assessment of patients, pharmacokinetic studies
were also performed. In all of the species examined
to date, PMM undergoes extensive metabolism via.
oxidative N-demethylation (Figure 2). (Broggini et
al., 1981; Morimoto et al., 1980; Ames et al., 1979;
Casper et al., 1981; Idhe et al., 1981; Benvenuto et
al., 1981; Rutty et al., 1982). N-Methylolmelamines,
the intermediates generated during the oxidative N-
demethylation of N-methylmelamines (Gescher et
al., 1980; Rutty et al., 1982), are considerably more
toxic than N-methylmelamines in vitro (Rutty &
Connors, 1977; Rutty & Abel, 1980). Thus
metabolism is thought to be a prerequisite for in vivo
anti-tumour activity with N-methylolmelamines
acting as the cytotoxic species. The mechanism of
action of N-methylolmelamines is, however, still
uncertain.
To ascertain the rate and extent of PMM
metabolism in man, plasma levels of the parent drug
and the first two products of oxidative N-
demethylation i.e. N2,N2,N4,N6-tetramethyl-
melamine (TMM) and N2,N4,N6-trimethylmelamine
(TRIMM) were measured (Figure 2). Certain
aspects of this study have previously been reported
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Figure 2 The oxidative N-demethylation of PMM
in a preliminary form (Newell et al., 1980; Smith et
al., 1980).
Materials and methods
Patient selection
The patients entered in the PMM Phase I clinical
study were all under the care of the Royal Marsden
Hospital. All patients had histologically confirmed
malignant tumours which had failed to respond to
conventional therapy. Additional criteria required
for eligibility to enter into the study included: WBC
and platelet count >3000uMI-' and
> 100,000pM 11 respectively; blood urea and
serum creatinine <8mM ,MI1- and < 106pM 1
respectively.
None of the patients had received cancer
chemotherapy or radiotherapy during the 3-week
period preceding their entry into the study. All
patients had a performance status of greater than
50% (Karnofsky scale) and a life expectancy of at
least 8 weeks. The treatment protocol was approved
by the Ethical Committee of the Royal Marsden
Hospital and informed consent was obtained from
all patients prior to entry into the study. The
general characteristics of the 17 patients, are
summarised in Table I.
Drug supply,formulation and administration
PMM used in the clinical study was greater than
99.5% pure. It was supplied by Prof. W.C.J. Ross of
the Chester Beatty Research Institute, London, as a
white crystalline powder. PMM (2mgml-') was
infused intravenously as a 2% ethanol 5% dextrose
solution after micropore (0.22pm) filtration. All
formulated PMM infusions were used within 24h of
preparation, as a sterility precaution. PMM was
initially given at a dose of 00mg m-2 and the dose
escalated to 1300mgm-2 according to a modified
Fibonacci scheme (Table II). At higher PMM doses,
requiring large infusion volumes, the infusion time
was extended from 1 to 4h. No dose escalation was
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carried out in the same patient. Three patients were
treated at each dose level at 3 weekly intervals, each
patient receiving a maximum of 3 courses. The rate
of infusion was regulated by using Tekmar TD51
pumps (International Medical Group, Oxton, UK).
Antimetics were administered whenever this was
considered necessary (droperidol, metochlopramide
and prochlorperazine).
Table I Patient characteristics
No. ofpatients
Sex: Male
Female
Age: Median
Range
Tumour types:
1. Bronchogenic carcinoma
Squamous cell-A
Adenocarcinoma 2
Oat cell-3
2. Breast carcinoma
3. Colon carcinoma
4. Hodgkin's disease
5. Adenocarcinoma-primary
unknown
17
11
6
54
28-68
9
4
2
1
Prior therapy:
5 patients had received no prior chemotherapy
Table II Dose escalation scheme
Infusion Infusion
Dose volume time
(mgm-2) (mO (h)
100 300 1
200 300 1
300 300 1
500 500 2
800 750 3
1300 1300 4
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Clinical evaluation ofpatients
Prior to entry into the study all patients had a
complete medical history and physical examination
including a detailed neurological examination. The
following laboratory investigations were performed
in order to establish the baseline data: Complete
blood count, liver function tests (serum bilirubin, y-
glutamyl transferase, alanine transaminase and
alkaline phosphatase), blood urea, serum creatinine,
uric acid, serum albumin and electrolytes. Tumour
size was measured by palpation and with the aid of
X-ray and liver, brain and bone scans where
applicable.
Haematological toxicity induced by PMM was
assessed by repeat blood counts before each course
and on days 5 and 8 following PMM infusion. A
WBC count between 2000-3000pl- 1 was regarded as
mildmyelosuppression,thosebetween 1000-2000MI- 1
moderate and those under 1000pl - 1 as severe myelo-
suppression. Platelet counts of 80-100 x 103pl1- and
50-80 x IO3pl1- ' were considered mild and moderate
thrombocytopenia respectively, while counts
<50,000MI- 1 were classified as severe.
Gastrointestinal side effects as evidenced by
nausea and vomiting were evaluated by direct
questioning of the patient and by a 24h clinical
observation of the patient in the hospital following
PMM infusion. The severity of vomiting was
assessed in terms of duration, frequency and the
need for anti-emetics in its control. Vomiting once
or twice during the infusion and requiring no anti-
emetics was classified as mild, while vomiting that
persisted up to 6h after infusion and requiring a
maximum administration of two courses of anti-
emetics was regarded as moderate. Vomiting was
classified as severe if it continued up to 24h after
PMM infusion and/or could only be controlled
partially by repeated doses of anti-emetics.
Pharmacokinetic studies
At various times during and after the PMM
infusion, 7ml blood samples were removed via an
indwelling intravenous cannula from the arm not
receiving the i.v. infusion. In general samples were
taken mid-way during the infusion, at the end of
the infusion and at 15, 30, 60, 120, 180 min post
infusion. Blood was placed in heparinised tubes
(10i.u.ml-1) and plasma prepared immediately by
centrifugation at 600g for 10 min. Plasma samples
were frozen and stored at -20°C until analysis.
Samples were assayed for PMM, N2,N2,N4,N6-
tetramethylmelamine (TMM) and N2,N4,N6-tri-
methylmelamine (TRIMM) by gas liquid
chromatography as previously described (Rutty et
al., 1982). The GLC assay used measured these
compounds over the range 1-1OO,uM for PMM and
TMM and 5-1OOpM for TRIMM.
Insufficient blood samples were taken during the
infusion to determine whether or not steady-
state PMM plasma levels had been achieved.
Furthermore, the distribution phase immediately
after the infusion could not be described again
because of insufficient numbers of samples.
However, from 15-180min post infusion, an
exponential equation describing the overall
elimination phase of the drug was fitted to the
PMM plasma levels:
C=Ae kt
Where C is the concentration at time t, A is a
concentration term and k is the overall first-order
elimination rate constant. The PMM elimination
phase half-life (tj) was calculated by:
0.693
2 k
The mono-exponential equation was fitted by a
computerised non-linear least squares analysis
(Sampson, 1969). The plasma levels of TMM and
TRIMM were plotted manually using the mean of
duplicate estimations on each plasma sample. Blood
samples were not taken for long enough to describe
the elimination phases of TMM and TRIMM.
Areas under the plasma concentration versus time
curves (AUC) were determined by the trapezoidal
rule.
Results
Toxicity
Nausea and vomiting emerged as being the most
frequent and the major dose limiting side effects of
PMM. The severity of the nausea and vomiting was
dose dependent (Table III). Nausea and vomiting was
severe enough to necessitate the administration of
anti-emetics at doses of 500mgm-2 and above. The
extreme severity of nausea and vomiting and its
poor control with anti-emetics precluded dose
escalation above 1300mgm2.
Table III PMM toxicity
No. of No. of Nausea/vomiting
(mgm-2) patients courses Frequency Intensity
100 3 7 0/7 Mild
200 3 7 1/7 4
300 3 5 2/5 Moderate
500 3 8 8/8 4
800 3 7 7/7 Severe
1300 2 4 4/4 430 J.R.F. MUINDI, D.R. NEWELL, I.E. SMITH & K.R. HARRAP
The assessment of acute neurological side effects
of PMM at doses of 500mgm-2 and above was not
possible because of the large doses of anti-emetics
used. At lower doses of PMM where this
assessment was possible, no neurological side effects
were observed. Although patients receiving
500mgm-2 of PMM and above complained of
somnolence this was probably due to the anti-
emetics; however, a contribution due to PMM
cannot be excluded.
Two patients developed pruritic erythematous
maculopapular skin rashes while receiving PMM.
These patients were on other drugs (analgesics and
sedatives) as well as PMM. It is possible that the
skin rashes were due to the other medications. One
patient who developed the skin rash while receiving
his 2nd course of 200mgm-2 PMM did not develop
the rash on his 3rd course. The 2nd patient
developed the skin rash while receiving his first
course of 1300mgg-2 PMM but was never
rechallenged at a later date.
Haematological toxicity was not seen in this
study.
Four patients had clinical evidence of hepatic
metastasis at the time of entry into the study. All of
these 4 patients failed to survive long enough to
receive a second course of PMM. Hepatic
metastases were confirmed at post mortem in all
these patients. The primary cause of death in all
cases was extensive systemic cancer. In no patient
was the immediate cause of death attributed to
PMM toxicity.
No complete or partial responses were observed
in this study. One minor response was observed at
a dose of 500 mg m 2 PMM in a patient with
squamous cell carcinoma of bronchus.
Pharmacokinetic studies
The pharmacokinetics of PMM were studied in 2
patients at each dose level up to, and including,
500mgm-2.Atdoses >500mgm 2theseverenausea
and vomiting prevented the frequent blood
sampling necessary for these studies. PMM overall
elimination phase half-lives (tj) and AUC values for
PMM, TMM and TRIMM are given in Table IV. In
2 patients (MS and MM) PMM pharmacokinetics
in the disposition phase were not first-order. With
respect to PMM pharmacokinetics, two distinct
groups of patients were observed. Those with
normal liver function had a significantly more rapid
PMM t4 (65+6min, mean+SEM, n=3) than
patients with hepatic disease and abnormal liver
function tests (138 +8min, n= 3), P=0.002. Patients
were determined to have abnormal liver function
by the following criteria: EH alanine transaminase
42 IUl-', JB bilirubin 177,uMl-1, PP y-glutamyl-
transferase 800 IUI1'. Within the group of patients
who received PMM as a 1 h infusion, 100-
300mgm 2, plasma levels at the end of the infusion
were directly related to dose, r=0.94, P=0.005. The
PMM plasma levels in all the patients studied are
shown in Figure 3.
TMM and TRIMM were detected as PMM
metabolites in the plasma of all the patients studied.
In those patients with normal liver function these 2
metabolites were present in greater concentrations
than the parent drug 2h after the end of the
infusion, e.g. Figure 4. Three other metabolites
were observed, namely- N2,N2,N4,N4-tetra-
methylmelamine, N2,N2,N4-trimethylmelamine and
N2,N4-dimethylmelamine. The first 2 metabolites,
structural isomers of TMM and TRIMM, were
present only in minor quantities whilst the GLC
assay employed could only measure N2,N4-
dimethylmelamine qualitatively due to the poor and
variable extraction of this compound from plasma.
Discussion
The Phase I clinical trial of PMM reported in the
present study has demonstrated that the dose-
limiting toxicities for this drug are nausea and
vomiting. This observation is in agreement with all
the Phase I clinical trial data previously reported
for PMM (Goldberg et al., 1980; Casper et al., 1981;
Ihde et al., 1981; Van Echo et al., 1980; Ajani et al.,
1982) and is thus apparently independent of the
schedule used. No other toxicity was consistently
observed in the present study i.e. haematological,
hepatic or renal. The absence of haematological
toxicity is also consistent with the other Phase I
studies of PMM with the exception of Goldberg et
al. (1980) who reproducibly induced haematological
toxicity with 1.2g/m2/day x 10. However the severe
nausea, vomiting and neurological toxicity of this
schedule led these authors to recommend that
Phase II studies of PMM should not be performed.
Preclinical toxicological studies with PMM
predicted the possibility of acute and severe
neurological side effects being seen in the clinical
studies with this drug (NCI PMM clinical brochure,
NCI, Bethesda, Md, 1978). Neurological side effects
have been noted in all of the Phase I clinical studies
previously reported. Neurological side effects were
not seen in the study reported here, probably
because of the lower PMM doses which were
administered although at higher doses the
administration of anti-emetics complicated the
assessment.of acute neurological side effects.
The pharmacokinetic studies performed during
this Phase I trial of PMM have provided useful
information, particularly in comparison to HMM.
Unlike orally administered HMM (D'Incalci et al.,
1978), i.v. PMM produced plasma levels of thePENTAMETHYLMELAMINE PHASE I STUDY 31
Table IV PMM pharmacokinetics
Area under the plasma conc. v.
PMM PMM time curve (IM xmin)
dose Hepatic plasma total
Patient (mgm-2) function tfl1,2 (min+s.e.) PMM TMM TRIMM methylmelamines
M.S. 100 Normal N.D.* 317 151 189 657
A.K. 100 Normal 54.1+ 3.5 734 204 573 1511
M.M. 200 Normal N.D.* 1694 397 1070 3161
A.O. 300 Normal 72.8+ 6.0 6232 3697 4091 14020
A.C. 500 Normal 68.6+ 3.6 3940 2693 3710 10343
E.H. 200 Abnormal 135.0+ 14.1 7175 1804 1438 10417
J.B. 300 Abnormal 152.6+ 9.0 6019 2121 627 8767
P.P. 500 Abnormal 127.0+ 11.1 7179 6206 7995 21380
*N.D.=PMM pharmacokinetics not first-order.
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Figure 3 PMM plasma levels in man. All infusions
given over 1 hour except AC (2h) and PP (3h)
(broken lines). Open symbols are patients with
abnormal hepative function. For doses see Table IV.
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parent drug which were directly related to the dose
administered. D'Incalci et al. (1978) administered
HMM over the dose range 120-300mgm 2 (0.90
+ 0.11 mMm-2, mean +SEM, 11 patients) and
measured plasma HMM levels during the first 12h
period. HMM AUC calculations for the majority of
patients (9/11) indicated that lower levels of the
parent drug were being achieved than was observed
with PMM (100-300mgm 2, 1.02+0.19mMm-2, n
=6) in the present study (HMM, AUC 0-12h=763
+163 iMxmin, n=9; PMM AUC 0-12h=4337
+ 1534uM x min; ratio HMM:PMM = 1:5.7; sig.
diff P =0.03). In agreement with this observation are
the preclinical studies of Ames et al. (1979) who
compared the pharmacokinetics of both HMM and
PMM in rabbits following i.v. and oral
administration. These authors reported substantially
higher levels of both parent compounds after i.v.
administration although the urinary excretion of
drug-derived material (75-85% dose admin.) was
independent of the route of administration. It was
concluded that the lower plasma levels of the parent
I
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drugs, followed oral administration, were due to
extensive first-pass hepatic metabolism rather than
poor absorption from the gastrointestinal tract. As
metabolism is thought to be a prerequisite for anti-
tumour activity (Rutty & Connors, 1977;_ Rutty et
al., 1982), the extensive first-pass hepatic
metabolism of orally administered methylmelamines
may be advantageous and thus i.v. administration
of PMM disadvantageous.
The importance of the liver in determining PMM
pharmacokinetics is emphasised by the observation
of a prolonged PMM t4 in patients with impaired
liver function (Table IV). This observation has also
been made by Benvenuto et al. (1981) who were
able to show a correlation between the incidence of
CNS toxicity, prolonged PMM disposition phase
half-lives and liver disease.
Although the objective of a Phase I trial is not
to assess the antitumour activity of a new drug
responses are obviously noted as an indication of
potential activity. Of the 173 patients who have
received PMM, only 7 minor responses (Van Echo
et al., 1980; Ajani et al., 1982 and the present study)
and 1 partial response (Casper et al., 1981) have
been observed. Thus, in view of the extremely severe
nausea and vomiting induced by PMM, and in the
absence of any proven superiority over HMM,
PMM is unlikely to find a place in routine clinical
use. The low response rates of tumours to HMM as
a single agent and the narrow spectrum of activity
(Legha et al., 1976) would necessitate a comparative
trial of HMM and PMM in a large number of
patients of selected tumour types to establish
whether or not there is a difference between these
two drugs. Such a trial is not contemplated
although PMM may be of value as an alternative
to HMM for patients who, due to G.I.T. obstructive
disease, cannot receive HMM.
In a study performed in conjunction with this
Phase I trial of PMM it was shown that PMM
metabolites capable of releasing formaldehyde were
not detectable (<50,uM) in the plasma of any
of these patients (Rutty et al., 1982). In experi-
mental animals such metabolites, possibly N-
methylolmelamines, were present in substantial
quantities; rats 211 yM, mice 563-773pM. These
authors suggested that the clinical activity of PMM,
and by analogy HMM, may be limited by the slow
rate of methylmelamine metabolism in man with
the consequence that cytotoxic levels of N-
methylolmelamines are not achieved. Thus a more
profitable approach would be the direct
administration of an activated form of both HMM
and PMM i.e. an N-methylolmelamine. The activity
of such a compound would not be limited by host
metabolism, whilst the greater water solubility of N-
methylolmelamines (Cumber & Ross, 1977) and
their lack of dependence on hepatic metabolism
would not necessitate oral administration.
N2,N,N6-trimethyl-N2,N4,N6-trimethylolmelamine
is currently under preclinical study in this respect
(Newell et al., 1981).
In conclusion, this Phase I trial of PMM has
demonstrated that the drug can be administered
intravenously to man. The dose-limiting toxicities of
PMM were nausea and vomiting which was severe
and occurred in all patients at doses .500mg/M2.
Haematological, renal or hepatic toxicities were not
observed. Pharmacokinetic studies have shown that
abnormal liver function is associated with a
prolonged PMM disposition phase half-life.
Comparison with previously published data
concerning HMM suggests that i.v. PMM gives rise
to greater (six-fold) AUC values for the parent drug
than does oral HMM.
In view of the severe toxicity of PMM, and the
low response rates and narrow spectrum of activity
of HMM, PMM is unlikely to contribute
significantly to the chemotherapy of cancer and
hence Phase II trials of PMM are not
recommended.
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